About Zymeworks
Zymeworks is a company based in Vancouver (Canada) founded in 2003. It operates as a Professional Services. Zymeworks has raised $145.97 million across 15 funding rounds from investors including Lilly, Northleaf and Celgene. The company has 286 employees as of December 31, 2024. Zymeworks has completed 1 acquisition, including Kairos Therapeutics. Zymeworks offers products and services including ZW1528 and ZW171. Zymeworks operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Vancouver, Canada
- Employees 286 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Zymeworks Inc.
-
Annual Revenue
$76.3 M0.38as on Dec 31, 2024
-
Net Profit
$-122.7 M-3.39as on Dec 31, 2024
-
EBITDA
$-108.63 M10.04as on Dec 31, 2024
-
Total Equity Funding
$145.97 M (USD)
in 15 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Dec 26, 2023
-
Investors
Lilly
& 13 more
-
Employee Count
286
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Zymeworks
Zymeworks is a publicly listed company on the NASDAQ with ticker symbol ZYME in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Zymeworks
Zymeworks offers a comprehensive portfolio of products and services, including ZW1528 and ZW171. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Preclinical data on ZW1528 is presented for respiratory research.
Development of ZW171 was discontinued for mesothelin targeting.
Unlock access to complete
Unlock access to complete
Leadership Team
20 people
Software Development Team
10 people
Finance and Accounting
10 people
Senior Team
6 people
Legal and Compliance
4 people
Manager Team
3 people
Product Management Team
3 people
Data Analysis and Operations Team
3 people
Unlock access to complete
Funding Insights of Zymeworks
Zymeworks has successfully raised a total of $145.97M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(01 May 2005)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Post-IPO - Zymeworks | Valuation |
investors |
|
| Jan, 2016 | Amount | Series A - Zymeworks | Valuation | CTI Life Sciences Fund , Fonds de solidarite FTQ |
|
| Feb, 2015 | Amount | Series A - Zymeworks | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Zymeworks
Zymeworks has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Northleaf and Celgene. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in life sciences companies.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Diversified investment management is conducted by Teralys Capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Zymeworks
Zymeworks has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kairos Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
An antibody-drug conjugate platform is developed for cancer treatments.
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Zymeworks
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Zymeworks Comparisons
Competitors of Zymeworks
Zymeworks operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Zymeworks
Frequently Asked Questions about Zymeworks
When was Zymeworks founded?
Zymeworks was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Where is Zymeworks located?
Zymeworks is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Is Zymeworks a funded company?
Zymeworks is a funded company, having raised a total of $145.97M across 15 funding rounds to date. The company's 1st funding round was a Series A of $1.79M, raised on May 01, 2005.
How many employees does Zymeworks have?
As of Dec 31, 2024, the latest employee count at Zymeworks is 286.
What is the annual revenue of Zymeworks?
Annual revenue of Zymeworks is $76.3M as on Dec 31, 2024.
What does Zymeworks do?
Novel biotherapeutics are engineered by Zymeworks to address difficult-to-treat cancers and other serious diseases. A fully integrated RD engine is utilized, spanning target selection to pivotal studies, supported by world-class researchers. Focus is placed on areas with high unmet medical needs, leveraging antibody-drug conjugates and multispecific antibody therapeutics technology platforms. A growing pipeline of multifunctional therapeutics is maintained to deliver transformational therapies globally through partnerships and collaborations.
Who are the top competitors of Zymeworks?
Zymeworks's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Zymeworks offer?
Zymeworks offers ZW1528 and ZW171.
Is Zymeworks publicly traded?
Yes, Zymeworks is publicly traded on NASDAQ under the ticker symbol ZYME.
How many acquisitions has Zymeworks made?
Zymeworks has made 1 acquisition, including Kairos Therapeutics.
Who are Zymeworks's investors?
Zymeworks has 14 investors. Key investors include Lilly, Northleaf, Celgene, Perceptive Advisors, and EcoR1.
What is Zymeworks's ticker symbol?
The ticker symbol of Zymeworks is ZYME on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.